Table 1.
Association between SMARCA4 and SMARCA2 mRNA expression and clinicopathological factors in the liver hepatocellular carcinoma dataset from TCGA.
| Factor | SMARCA4 expression | SMARCA2 expression | ||||
|---|---|---|---|---|---|---|
| High expressiona n = 37 |
Lower expressionb n = 335 |
P value | High expressiona n = 37 |
Lower expressionb n = 335 |
P value | |
| Age | 57.4 ± 13.5 | 59.7 ± 13.5 | 0.30c | 60.8 ± 12.2 | 59.3 ± 13.6 | 0.49c |
| Gender | 0.01 d | 0.70d | ||||
| Male | 18 (48.6%) | 233 (69.6%) | 24 (64.9%) | 227 (67.8%) | ||
| Female | 19 (51.4%) | 102 (30.4%) | 13 (35.1%) | 108 (32.2%) | ||
| Tumor Stage (T) | 0.008 d | 0.29d | ||||
| T1 + T2 | 21 (56.8%) | 255 (76.8%) | 25 (67.6%) | 251 (75.6%) | ||
| T3 + T4 | 16 (43.2%) | 77 (23.2%) | 12 (32.4%) | 81 (24.4%) | ||
| Tumor Stage (S) | 0.010 d | 0.11d | ||||
| SI + SII | 19 (55.9%) | 239 (79.1%) | 22 (62.9%) | 236 (75.4%) | ||
| SIII + SIV | 15 (44.1%) | 75 (23.9%) | 13 (37.1%) | 77 (24.6%) | ||
| Lymph node metastasis | 0.014 d | 0.99d | ||||
| N0 | 27 (93.1%) | 226 (99.1%) | 25 (96.2%) | 228 (98.7%) | ||
| N1 | 2 (6.9%) | 2 (0.9%) | 1 (3.8%) | 3 (1.3%) | ||
| Metastasis Stage Code | 0.51d | 0.27d | ||||
| M0 | 30 (100%) | 235 (98.3%) | 24 (96.0%) | 243 (98.8%) | ||
| M1 | 0 (0.0%) | 4 (1.7%) | 1 (4.0%) | 3 (1.2%) | ||
| Histological grade | 0.004 d | 0.019 d | ||||
| G1 + G2 | 15 (41.7%) | 218 (65.9%) | 30 (81.1%) | 203 (61.5%) | ||
| G3 + G4 | 21 (58.3%) | 113 (34.1%) | 7 (18.9%) | 127 (38.5%) | ||
aDecile of the tumor population with higher levels of SMARCA4 or SMARCA2 mRNA.
bRest of the tumors not included in the high expression decile.
cStudent’s t-test.
dChi-square test. Significant P values (P ≤ 0.05) are depicted in bold.